【レポートの概要（一部）】
1. Report Overview
1.1 Global Asthma and COPD Therapies Market Overview
1.2 Global Asthma and COPD Therapies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Asthma and COPD Therapies
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 Overview of Respiratory Diseases
2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive
2.3 What is Asthma?
2.3.1 Trends in Asthma Prevalence
2.3.2 Pathophysiology of Asthma
2.3.3 Symptoms of Asthma
2.3.4 Causes and Triggers for Asthma
2.3.5 Treatment of Asthma
2.3.6 Guidelines for Asthma Treatment
2.3.7 Drug Treatments for Asthma
2.3.8 Drug Delivery Methods in Asthma
2.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
2.4.1 Trends in COPD Prevalence
2.4.2 Pathophysiology of COPD
2.4.3 Signs and Symptoms of COPD
2.4.4 Treatment of COPD
2.4.5 Drug Treatments for COPD
2.4.6 Guidelines for COPD Treatment
2.5 Major Drug Classes in the Treatment of Asthma and COPD
2.5.1 Bronchodilators
2.5.1.1 Beta2-Agonists
2.5.1.2 Anticholinergics
2.5.2 Anti-Inflammatory Drugs
2.5.2.1 Corticosteroids
2.5.2.2 Leukotriene Receptor Antagonists
2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
2.5.3 Combination Drugs
2.5.4 Drugs for Allergic Rhinitis
2.6 Phases of Clinical Trials
2.7 Scope of this Report
2.8 Currency Exchange Rates in This Report
3. Asthma and COPD Therapies: World Market 2014-2024
3.1 The World Respiratory Drugs Market by Therapeutic Area
3.2 The World Asthma and COPD Therapies Market in 2013
3.2.1 Leading Asthma and COPD Therapies
3.2.2 Leading Companies in the Asthma and COPD Therapies Market
3.3 World Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2014-2024
3.3.1 World Asthma Therapies Market: Sales Forecast 2014-2024
3.3.2 World COPD Therapies Market: Sales Forecast 2014-2024
3.4 World Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2014-2024
3.5 Combination Drugs Lead the Asthma and COPD Therapies Market
3.6 How Will Segmental Market Shares Change to 2024?
3.6.1 World Asthma and COPD Therapies Market: Drivers and Restraints 2014-2024
3.7 Asthma and COPD Therapies: Trends and Developments
3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?
4. Leading National Markets 2014-2024
4.1 Regional Breakdown of the World Asthma and COPD Therapies Market
4.2 World Asthma and COPD Therapies Market: Regional Forecast 2014-2024
4.2.1 How Will Regional Market Shares Change to 2024?
4.3 National Breakdown of the World Asthma and COPD Therapies Market
4.4 World Asthma and COPD Therapies Market: National Markets Forecast 2014-2024
4.4.1 How Will National Market Shares Change to 2024?
4.5 The US Asthma and COPD Therapies Market 2014-2024
4.5.1 US Asthma and COPD Therapies Market Forecast 2014-2024
4.5.2 US Asthma and COPD Therapies Market: Trends and Developments
4.5.2.1 Increasing COPD Prevalence in the US
4.5.2.2 FDA Issues Draft Guidance on Generic Inhaler Bioequivalence
4.5.2.3 Pharmacy Benefit Managers Alter Formulary Status of Advair
4.6 Japanese Asthma and COPD Therapies Market 2014-2024
4.6.1 Japanese Asthma and COPD Therapies Market Forecast 2014-2024
4.6.2 Japanese Asthma and COPD Therapies Market: Trends and Developments
4.6.2.1 Generic Penetration to Reach 60% by 2018?
4.6.2.2 Japanese Pharmaceutical Industry Regulatory Reform
4.7 EU5 Asthma and COPD Therapies Market 2014-2024
4.7.1 German Asthma and COPD Therapies Market Forecast 2014-2024
4.7.2 French Asthma and COPD Therapies Market Forecast 2014-2024
4.7.3 UK Asthma and COPD Therapies Market Forecast 2014-2024
4.7.4 Italian Asthma and COPD Therapies Market Forecast 2014-2024
4.7.5 Spanish Asthma and COPD Therapies Market Forecast 2014-2024
4.7.6 EU5 Asthma and COPD Therapies Market: Trends and Developments
4.7.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
4.7.6.2 France: Social Security Finance Bill 2014
4.7.6.3 UK: Improving Asthma and COPD Patient Outcomes
4.7.6.4 Italy: Austerity Measures Limiting Growth
4.7.6.5 Spain: The Start of Recovery in the Spanish Economy
4.8 BRIC Asthma and COPD Therapies Market 2014-2024
4.8.1 Chinese Asthma and COPD Therapies Market Forecast 2014-2024
4.8.2 Chinese Asthma and COPD Therapies Market: Trends and Developments
4.8.2.1 China’s Industrial Future and Asthma/COPD
4.8.2.2 Expansion of Healthcare Coverage and Reimbursement
4.8.2.3 Price Controls and the Anhui Model
4.8.3 Brazilian Asthma and COPD Therapies Market Forecast 2014-2024
4.8.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments
4.8.4.1 Increasing Access to Medicines
4.8.5 Indian Asthma and COPD Therapies Market Forecast 2014-2024
4.8.6 Indian Asthma and COPD Therapies Market: Trends and Developments
4.8.6.1 Drug Prices Control Order 2013
4.8.6.2 Expansion of Healthcare Provision
4.8.7 Russian Asthma and COPD Therapies Market Forecast 2014-2024
4.8.8 Russian Asthma and COPD Therapies Market: Trends and Developments
4.8.8.1 No Embargo on Foreign Drug Imports
4.8.8.2 Pharma2020 and the Russian Pharmaceutical Industry
4.9 Mexican Asthma and COPD Therapies Market 2014-2024
4.9.1 Mexican Asthma and COPD Therapies Market Forecast 2014-2024
4.9.2 Mexican Asthma and COPD Therapies Market: Trends and Developments
4.9.2.1 Seguro Popular: Mexican Healthcare Reform
4.9.2.2 COFEPRIS: Regulatory Changes and Improvements
4.9.2.3 Mexico’s Agreement for Innovation
5. Bronchodilator Monotherapy Market 2014-2024
5.1 Introduction to Bronchodilator Monotherapy
5.2 The Bronchodilator Monotherapy Market in 2013
5.2.1 Leading Bronchodilators in 2013
5.3 Bronchodilator Monotherapy: Market Forecast 2014-2024
5.4 How Will Market Shares by Drug Class Change to 2024?
5.5 The Short-Acting Beta2-Agonist (SABA) Market 2014-2024
5.5.1 Leading SABAs in 2013
5.5.2 SABAs: Market Forecast 2014-2024
5.5.3 Market Share of Leading SABAs to 2024
5.5.4 Ventolin (salbutamol, GSK)
5.5.4.1 Ventolin: Sales Forecast 2014-2024
5.5.5 ProAir (salbutamol, Teva)
5.5.5.1 ProAir: Sales Forecast 2014-2024
5.5.6 Proventil (salbutamol, Merck)
5.5.6.1 Proventil: Sales Forecast 2014-2024
5.5.7 Xopenex (levosalbutamol, Dainippon Sumitomo)
5.5.7.1 Xopenex: Sales Forecast 2014-2024
5.6 The Long-Acting Beta2-Agonist (LABA) Market 2014-2024
5.6.1 Leading LABAs in 2013
5.6.2 LABAs: Market Forecast 2014-2024
5.6.3 Market Share of Leading LABAs to 2024
5.6.4 Foradil (formoterol, Merck/Novartis)
5.6.4.1 Foradil: Sales Forecast 2014-2024
5.6.5 Serevent (salmeterol, GSK)
5.6.5.1 Serevent: Sales Forecast 2014-2024
5.6.6 Arcapta/Onbrez (indacaterol, Novartis)
5.6.6.1 Arcapta/Onbrez: Sales Forecast 2014-2024
5.6.7 Brovana (arfomoterol, Dainippon Sumitomo)
5.6.7.1 Brovana: Sales Forecast 2014-2024
5.6.8 Striverdi (olodaterol, Boehringer Ingelheim)
5.6.8.1 Striverdi: Sales Forecast 2014-2024
5.7 The Anticholinergics Market 2014-2024
5.7.1 Leading Anticholinergics in 2013
5.7.2 Anticholinergics: Market Forecast 2014-2024
5.7.3 Market Share of Leading Anticholinergics to 2024
5.7.4 Spiriva (tiotropium, Boehringer Ingelheim)
5.7.4.1 Spiriva: Sales Forecast 2014-2024
5.7.5 Spiriva: Recent Developments
5.7.5.1 Safety Concerns and the UPLIFT Trial
5.7.5.2 Results of the POET Study
5.7.5.3 Competition from Combination Products
5.7.6 Atrovent (ipratropium, Boehringer Ingelheim)
5.7.6.1 Atrovent: Sales Forecast 2014-2024
5.7.7 Eklira/Tudorza/Bretaris (aclidinium, AstraZeneca/Forest/Menarini)
5.7.7.1 Eklira/Tudorza/Bretaris: Sales Forecast 2014-2024
6. Anti-Inflammatory Drugs Market 2014-2024
6.1 Introduction to Anti-Inflammatory Drugs
6.2 The Anti-Inflammatory Drugs Market in 2013
6.2.1 Leading Anti-Inflammatory Drugs in 2013
6.3 Anti-Inflammatory Drugs: Market Forecast 2014-2024
6.4 How Will Market Shares by Drug Class Change to 2024?
6.5 The Corticosteroids Market 2014-2024
6.5.1 Leading Corticosteroids in 2013
6.5.2 Corticosteroids: Market Forecast 2014-2024
6.5.3 Market Share of Leading Corticosteroids to 2024
6.5.4 Flixotide/Flovent (fluticasone propionate, GSK)
6.5.4.1 Flixotide/Flovent: Sales Forecast 2014-2024
6.5.5 Pulmicort (budesonide, AstraZeneca)
6.5.5.1 Pulmicort: Sales Forecast 2014-2024
6.5.6 QVAR (beclometasone, Teva)
6.5.6.1 QVAR: Sales Forecast 2014-2024
6.5.7 Asmanex (mometasone, Merck)
6.5.7.1 Asmanex: Sales Forecast 2014-2024
6.6 The Anti-Leukotrienes Market 2014-2024
6.6.1 Leading Anti-Leukotrienes in 2013
6.6.2 Anti-Leukotrienes: Market Forecast 2014-2024
6.6.2.1 Market Share of Leading Anti-Leukotrienes to 2024
6.6.3 Singulair (montelukast, Merck)
6.6.3.1 Singulair: Sales Forecast 2014-2024
6.7 The Monoclonal Antibodies Market 2014-2024
6.7.1 Monoclonal Antibodies: Market Forecast 2014-2024
6.7.1.1 Market Share of Leading Monoclonal Antibodies to 2024
6.7.2 Xolair (omalizumab, Novartis/Roche)
6.7.2.1 Xolair: Sales Forecast 2014-2024
6.7.3 Cinquil (reslizumab, Teva)
6.7.3.1 Cinquil: Sales Forecast 2014-2024
6.7.4 Mepolizumab (Bosatria, GSK)
6.7.4.1 Mepolizumab: Sales Forecast 2014-2024
6.7.5 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
6.7.5.1 Benralizumab: Sales Forecast 2014-2024
6.7.6 Lebrikizumab (RG3637, Roche)
6.7.6.1 Lebrikizumab: Sales Forecast 2014-2024
6.7.7 Dupilumab (REGN668, Regeneron/Sanofi)
6.7.7.1 Dupilumab: Sales Forecast 2014-2024
7. Combination Drugs Market 2014-2024
7.1 Introduction to Combination Drugs
7.1.1 Leading Combination Drugs in 2013
7.2 Combination Drugs: Market Forecast 2014-2024
7.3 How Will Market Shares by Drug Change to 2024?
7.3.1 Advair/Seretide (fluticasone/salmeterol, GSK)
7.3.1.1 Advair/Seretide: Sales Forecast 2014-2024
7.3.2 Symbicort (budesonide/formoterol, AstraZeneca)
7.3.2.1 Symbicort: Sales Forecast 2014-2024
7.3.2.2 Symbicort: The SMART Concept
7.3.3 Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
7.3.3.1 Combivent: Sales Forecast 2014-2024
7.3.4 Dulera (formoterol/mometasone, Merck)
7.3.4.1 Dulera: Sales Forecast 2014-2024
7.4 Recently Launched Combination Drugs
8. Leading Companies in the Asthma and COPD Therapies Market
8.1 Asthma and COPD Therapies: Increasing Competition
8.1.1 Leading Companies in Asthma and COPD in 2013
8.1.2 Leading Companies: Market Forecast 2014-2024
8.1.3 How Will Leading Companies’ Market Shares Change to 2024?
8.2 AstraZeneca
8.2.1 AstraZeneca: Asthma and COPD Therapies
8.2.2 AstraZeneca: Sales Forecast 2014-2024
8.2.3 AstraZeneca: Products in Development
8.2.4 AstraZeneca: Recent Developments
8.2.4.1 AstraZeneca Acquires Almirall’s Respiratory Portfolio
8.2.4.2 Acquisition of Pearl Therapeutics Expanded AstraZeneca’s Combination Drug Pipeline
8.2.4.3 AstraZeneca Rejects Pfizer Takeover Bid
8.3 Boehringer Ingelheim
8.3.1 Boehringer Ingelheim: Asthma and COPD Therapies
8.3.2 Boehringer Ingelheim: Sales Forecast 2014-2024
8.3.3 Boehringer Ingelheim: Products in Development
8.3.4 Boehringer Ingelheim: Recent Developments
8.3.4.1 Expansion of Respimat Manufacturing Capacity
8.3.4.2 Respimat Safety Concerns and the TIOSPIR Study
8.3.4.3 Ben Venue Laboratories Shut Down
8.4 GSK
8.4.1 GSK: Asthma and COPD Therapies
8.4.2 GSK: Sales Forecast 2014-2024
8.4.3 GSK: Products in Development
8.4.4 GSK: Recent Developments
8.4.4.1 Breo/Relvar and Anoro: Recently Launched Combination Drugs
8.4.4.2 Arnuity Ellipta Approved in the US
8.4.4.3 GSK Divests OTC Products
8.4.4.4 GSK Asset Swap with Novartis to Restructure Consumer Health
8.4.4.5 GSK Presents Data on Eosinophil Levels and COPD
8.5 Merck & Co. (Merck)
8.5.1 Merck: Asthma and COPD Therapies
8.5.2 Merck: Sales Forecast 2014-2024
8.5.3 Merck: Products in Development
8.5.4 Merck: Recent Developments
8.5.4.1 Bayer Acquires Merck’s Consumer Health Business
8.5.4.2 FDA Rejects Singulair OTC Switch
8.5.4.3 Takeda Ended Co-Promotion of Daxas with Merck
8.6 Novartis
8.6.1 Novartis: Asthma and COPD Therapies
8.6.2 Novartis: Sales Forecast 2014-2024
8.6.3 Novartis: Products in Development
8.6.4 Novartis: Recent Developments
8.6.4.1 Novartis Restructures Following Strategic Review
8.6.4.2 Novartis Presents Data on Ultibro and Seebri
8.6.4.3 Pfizer Promotes Two Novartis COPD drugs in the UK
8.7 Roche
8.7.1 Roche: Asthma and COPD Therapies
8.7.2 Roche: Sales Forecast 2014-2024
8.7.3 Roche: Products in Development
8.8 Teva
8.8.1 Teva: Asthma and COPD Therapies
8.8.2 Teva: Sales Forecast 2014-2024
8.8.3 Teva: Products in Development
8.8.4 Teva: Recent Developments
8.8.4.1 Launch of DuoResp Spiromax
【レポート販売概要】
■ タイトル：世界の喘息及びCOPD（慢性閉塞性肺疾患）治療薬市場■ 英文：Asthma and COPD Therapies Market Forecast 2014-2024 : Opportunities for Leading Companies
■ 発行日：2014年10月
■ 調査会社：visiongain
■ 商品コード：VGAIN4120203
■ 調査対象地域：グローバル
- 添加剤マスターバッチの世界市場：抗菌剤、抗酸化剤、難燃剤、UV安定剤、蛍光染料、粘着防止剤、帯電防止剤Additive masterbatch market to reach USD 3.40 Billion by 2021, registering a CAGR of 6.0% between 2016 and 2021 The global additive masterbatch market is driven by the rising demand from emerging economies. Rapid industrialization in developing economies such as India, Indonesia, Brazil, and Mexico is expected to drive the global additive masterbatch market. The increasing use of plastics over oth …
- スマート照明市場2014(Version1)：市場動因、予測NanoMarkets has been covering the smart lighting market for four years and has acquired an understanding of the key markets, technologies and companies in this rapidly expanding business. This year, NanoMarkets has decided to cover this interesting sector in two volumes. Volume I is devoted to an analysis of smart lighting markets and covering the basic drivers and economics of the smart lighting …
- 温風暖房機の世界市場2016-2020：住宅用温風暖房器、非住宅用温風暖房器About warm air heater Warm air central heating units are used for space heating, and prove to be a competent alternative to traditional central heating systems. Electricity, oil, or natural gas are the most common means for fueling warm air heaters. The key advantage of installing a warm air heater is that the air is heated at a rapid pace, and is transferred directly where it is required via side …
- 農薬の世界市場分析：肥料、作物保護用化学品、植物成長調整剤The global agrochemicals market is expected to reach USD 308.92 billion by 2025, according to a new report by Grand View Research, Inc. The growing demand for crop protection chemicals, such as fungicides, herbicides, and insecticides, is expected to be the biggest driver of the agrochemicals industry over the forecast period. Shrinking arable land due to rapid industrialization and population exp …
- 髭用グルーミング製品の世界市場2019-2023About this market Introduction of celebrity-owned brands to drive market growth. The fashion industry has been experiencing rapid changes and advancements for the past two decades, mainly due to growing fashion-conscious people, especially in developing regions such as Asia. In addition, the endorsements and the use of fashion and grooming products such as beard grooming products act as a catalyst …
- Greenfields Petroleum Corporation：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Greenfields Petroleum Corporation Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Greenfields Petroleum Corporation Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The repor …
- パスタ・麺（ヌードル）市場の将来展望（～2018）：ベネズエラSummary The Future of the Pasta and Noodles Market in Venezuela to 2018 is the result of Canadean's extensive market research. The report presents detailed analysis on the Pasta and Noodles consumption trends in Venezuela, historic and forecast Pasta and Noodles consumption volumes and values at market and category level, brand share and distribution channel data. This report brings together Canad …
- 複合材料試験の世界市場予測：連続繊維複合材料、不連続繊維複合材料、ポリママトリックス複合材料、セラミックスマトリックス複合材料The global composites testing market is projected to reach USD 3.06 Billion by 2026, at a CAGR of 6.95%, from 2016 to 2026. The increasing penetration of composites in the aerospace & defense, transportation and wind energy applications and stringent composites testing standards, are the key factors responsible for the growth of the global composites testing market. The global composites testing m …
- 移動ロボットの世界市場：無人陸上車両(UGV)、無人航空機(UAV)、無人艇(UMV)About Mobile Robotics A mobile robot is an automatic machine that is not fixed to one position. It is capable of moving in an environment for which it is designed. It can function autonomously or can be remotely controlled. Mobile robots have been deployed in the Aerospace and Defense industry for many years; however, now these robots are gaining popularity among industrial and commercial applicat …
- ゲノム編集の世界市場分析：技術別（CRISPR、TALEN、ZFN）、送達方法別（体外、体内）、用途別（動物/植物細胞の編集）、サービス別（インハウス、委託）、エンドユーザー別、セグメント予測、2014-2025The global genome editing market is anticipated to reach USD 8.1 billion by 2025, according to a new report by Grand View Research, Inc. Key drivers attributing to the expansion include early applications of DNA editing to therapeutics. Use of the technology for the disease eradication through direct correction of disturbances in normal physiology, engineering the immune response, and alteration o …
- ツーリングの世界市場：ダイ＆金型、鍛造、ジグ＆治具、工作機械、ゲージThe global tooling market size is expected to reach $368.5 billion in 2026, from $200.8 billion in 2018, growing at a CAGR of 8.0% from 2019 to 2026. Tooling or tools are a fundamental part of every manufacturing industry. The tooling process includes molding, punching, forging, machining, boring, drilling, and gauging. The instruments required for this purpose include dies & molds and machine too …
- 油脂の世界市場予測（～2021年）：パーム油、大豆油、菜種油、ひまわり油、オリーブ油The fats & oils market is projected to grow at a CAGR of 4.4%, in terms of value, from 2016 to reach a projected value of USD 247.78 Billion by 2021. The market is driven by the demand from Asia-Pacific countries, particularly India, China, Malaysia, and Indonesia. Demand from the respective food sectors of these countries, which are supported by rise in living standards and population growth are …
- Abraxas Petroleum Corporation：石油・ガスの開発・生産動向及びコスト分析- Q2, 2013Abraxas Petroleum Corporation Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Abraxas Petroleum Corporation Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an …
- Electricite de France S.A.：石油・ガスバリューチェーン分析レポート2013Electricite de France S.A. Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Electricite de France S.A." Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Electricite de France S.A.”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chai …
- インドのHVAC（冷暖房空調設備）市場About HVAC systems HVAC systems help in maintaining air quality in residential and commercial establishments by adequately ventilating and filtering it, and ensuring thermal balance. Significant policies on refrigerant use, stringent and eco-friendly norms, safety pre-requisites, advances in technology, and efficient use of products and services have influenced the market players to improve their …
